• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    HilleVax, Inc. - Common Stock (NQ: HLVX )

    1.940 +0.080 (+4.30%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about HilleVax, Inc. - Common Stock

    HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax Announces Reduction in Force
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    HLVX Investors Have Opportunity to Join HilleVax, Inc. Securities Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
    Collaboration leverages HilleVax’s leading norovirus vaccine development expertise and adds a Phase 1-ready next-generation program to HilleVax’s pipeline 
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax to Present at Upcoming Investor Conferences
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax Announces Pricing of Public Offering of Common Stock
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax Announces Proposed Public Offering of Common Stock
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax Announces Executive Management Appointments and Promotions
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax to Participate in November Investor Conferences
    From HilleVax, Inc.
    Via GlobeNewswire
    HilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
    From HilleVax, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.